Hypokalemia-induced rhabdomyolysis as the first symptom of primary aldosteronism: a case report and literature review.
Study Design
- Jenis Studi
- Case Reports
- Ukuran Sampel
- 1
- Populasi
- 65-year-old woman with primary aldosteronism
- Intervensi
- Hypokalemia-induced rhabdomyolysis as the first symptom of primary aldosteronism: a case report and literature review. None
- Pembanding
- None
- Luaran Utama
- None
- Arah Efek
- Mixed
- Risiko Bias
- High
Abstract
Primary aldosteronism (PA) is a well-documented cause of secondary hypertension, often accompanied by hypokalemia. However, PA with normal blood pressure and hypokalemic rhabdomyolysis (RM) is rare. We report a case of hypokalemia-induced RM as the first symptom of PA. A 65-year-old woman was admitted due to intermittent limb weakness and myalgia. She denied a history of hypertension. Laboratory findings showed profound hypokalemia (1.8 mmol/L) and extreme elevation of creatinine kinase (CK) levels (18,370 U/L), suggestive of hypokalemia-induced RM. She was administered intravenous fluids as well as active oral and intravenous potassium supplements. CK and myoglobin levels gradually decreased, but the serum potassium recovery was poor. Further evaluations strongly suggested PA by an aldosterone-producing adenoma, which was surgically removed. After surgery, the patient recovered well. The systolic blood pressure decreased by approximately 10-20 mmHg and the diastolic blood pressure decreased by approximately 5-10 mmHg. After discontinuation of spironolactone and oral potassium supplementation, the patient had normal serum potassium levels. This case indicates that PA is a cause of hypokalemic RM, even in patients with normal blood pressure. In addition, attention should be paid to changes in serum aminotransferase levels associated with RM. If the patient had no liver disease, it might be a marker for skeletal muscle injury instead of hepatocyte damage.
TL;DR
This case indicates that PA is a cause of hypokalemic RM, even in patients with normal blood pressure, and attention should be paid to changes in serum aminotransferase levels associated with RM.
Used In Evidence Reviews
Similar Papers
Pharmacological research · 1999
Health benefits of docosahexaenoic acid (DHA).
Circulation · 2010
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
Contemporary clinical trials · 2012
The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.
Journal of clinical hypertension (Greenwich, Conn.) · 2011
Role of mercury toxicity in hypertension, cardiovascular disease, and stroke.
Progress in neuro-psychopharmacology & biological psychiatry · 2008
The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
The Cochrane database of systematic reviews · 2007